Fusarium Infections in Critically Ill Patients

Invasive mold infections (IMIs) are significant causes of infectious mortality in immunocompromised patients, such as those with hematologic malignancies and allogeneic bone marrow transplant recipients. Of the IMIs, invasive aspergillosis is by far the most common. Nevertheless, over the past decade, other filamentous molds, such as Fusarium species, have been increasingly reported as the cause of severe IMIs in these patient populations. Herein we critically review the epidemiology, pathogenesis, clinical presentation, diagnostic methods, and therapeutic approaches for invasive fusariosis in immunocompromised hosts. We also present the key characteristics and differentiating features of invasive fusariosis and invasive aspergillosis. Current therapeutic approaches for fusariosis are suboptimal, resulting in exceedingly high mortality rates. At present, prompt diagnosis along with rapid initiation of appropriate treatment and, more importantly, reconstitution of the host immune responses are critical for a favorable outcome of this devastating opportunistic mycosis.

Fusarium - invasive fusariosis - pneumonia - immunocompromised host - leukemia

REFERENCES

• 1 Marr K A, Carter R A, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.  Clin Infect Dis. 2002;  34 909-917
• 2 Anaissie E J, Bodey G P, Rinaldi M G. Emerging fungal pathogens.  Eur J Clin Microbiol Infect Dis. 1989;  8 323-330
• 3 Kontoyiannis D P, Bodey G P. Invasive aspergillosis in 2002: an update.  Eur J Clin Microbiol Infect Dis. 2002;  21 161-172
• 4 Boutati E I, Anaissie E J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.  Blood. 1997;  90 999-1008
• 5 Torres H A, Kontoyiannis D P. Hyalohyphomycoses (other than Aspergillosis and Penicilliosis). In: Dismukes WE, Pappas PG, Sobel JD Oxford Textbook of Clinical Mycology. 1st ed. New York; Oxford University Press 2003: 252-270
• 6 Anaissie E, Kantarjian H, Ro J et al.. The emerging role of Fusarium infections in patients with cancer.  Medicine (Baltimore). 1988;  67 77-83
• 7 Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme.  Br J Haematol. 2000;  111 272-276
• 8 Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients.  J Infect. 1994;  28(suppl 1) 7-15
• 9 Nelson P E, Dignani M C, Anaissie E J. Taxonomy, biology, and clinical aspects of Fusarium species.  Clin Microbiol Rev. 1994;  7 479-504
• 10 Pontón J, Ruchel R, Clemons K V et al.. Emerging pathogens.  Med Mycol. 2000;  38(suppl 1) S225-S236
• 11 Walsh T J, Groll A H. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century.  Transpl Infect Dis. 1999;  1 247-261
• 12 Rabodonirina M, Piens M A, Monier M F, Gueho E, Fiere D, Mojon M. Fusarium infections in immunocompromised patients: case reports and literature review.  Eur J Clin Microbiol Infect Dis. 1994;  13 152-161
• 13 Mayayo E, Pujol I, Guarro J. Experimental pathogenicity of four opportunist Fusarium species in a murine model.  J Med Microbiol. 1999;  48 363-366
• 14 Cho C T, Vats T S, Lowman J T, Brandsberg J W, Tosh F E. Fusarium solani infection during treatment for acute leukemia.  J Pediatr. 1973;  83 1028-1031
• 15 Groll A H, Walsh T J. Uncommon opportunistic fungi: new nosocomial threats.  Clin Microbiol Infect. 2001;  7(suppl 2) S8-S24
• 16 Richardson S E, Bannatyne R M, Summerbell R C, Milliken J, Gold R, Weitzman S S. Disseminated fusarial infection in the immunocompromised host.  Rev Infect Dis. 1988;  10 1171-1181
• 17 Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review.  Clin Infect Dis. 1992;  14(suppl 1) S43-S53
• 18 Perfect J R, Schell W A. The new fungal opportunists are coming.  Clin Infect Dis. 1996;  22(suppl 2) S112-S118
• 19 Costa A R, Valente N Y, Criado P R, Pires M C, Vasconcellos C. Invasive hyalohyphomycosis due to Fusarium solani in a patient with acute lymphocytic leukemia.  Int J Dermatol. 2000;  39 717-718
• 20 Freidank H. Hyalohyphomycoses due to Fusarium spp.: two case reports and review of the literature.  Mycoses. 1995;  38 69-74
• 21 Minor Jr R L, Pfaller M A, Gingrich R D, Burns L J. Disseminated Fusarium infections in patients following bone marrow transplantation.  Bone Marrow Transplant. 1989;  4 653-658
• 22 Guarro J, Gene J. Opportunistic fusarial infections in humans.  Eur J Clin Microbiol Infect Dis. 1995;  14 741-754
• 23 Musa M O, Al Eisa A, Halim M et al.. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years.  Br J Haematol. 2000;  108 544-548
• 24 Raad I I, Hachem R. Treatment of central venous catheter-related fungemia due to Fusarium oxysporum .  Clin Infect Dis. 1995;  20 709-711
• 25 Wheeler M S, McGinnis M R, Schell W A, Walker D H. Fusarium infection in burned patients.  Am J Clin Pathol. 1981;  75 304-311
• 26 Girmenia C, Arcese W, Micozzi A, Martino P, Bianco P, Morace G. Onychomycosis as a possible origin of disseminated Fusarium solani infection in a patient with severe aplastic anemia.  Clin Infect Dis. 1992;  14 1167
• 27 Gupta A K, Baran R, Summerbell R C. Fusarium infections of the skin.  Curr Opin Infect Dis. 2000;  13 121-128
• 28 Nuovo M A, Simmonds J E, Chacho M S, McKitrick J C. Fusarium solani osteomyelitis with probable nosocomial spread.  Am J Clin Pathol. 1988;  90 738-741
• 29 Anaissie E J, Kuchar R T, Rex J H et al.. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections.  Clin Infect Dis. 2001;  33 1871-1878
• 30 Raad I, Tarrand J, Hanna H et al.. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer.  Infect Control Hosp Epidemiol. 2002;  23 532-537
• 31 Clemons K V, Calich V L, Burger E et al.. Pathogenesis, I: Interactions of host cells and fungi.  Med Mycol. 2000;  38 99-111
• 32 Latge J P. Aspergillus fumigatus and aspergillosis.  Clin Microbiol Rev. 1999;  12 310-350
• 33 Rinehart J J, Balcerzak S P, Sagone A L, LoBuglio A F. Effects of corticosteroids on human monocyte function.  J Clin Invest. 1974;  54 1337-1343
• 34 Nucci M, Anaissie E, Queiroz-Telles F et al.. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.  Cancer. 2003;  98 315-319
• 35 Kontoyiannis D P, Bodey G P, Hanna H et al.. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery.  Leuk Lymphoma. 2004;  45 141-143
• 36 Sampathkumar P, Paya C V. Fusarium infection after solid-organ transplantation.  Clin Infect Dis. 2001;  32 1237-1240
• 37 Patel R, Paya C V. Infections in solid-organ transplant recipients.  Clin Microbiol Rev. 1997;  10 86-124
• 38 Cohen M S, Isturiz R E, Malech H L et al.. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi.  Am J Med. 1981;  71 59-66
• 39 Girmenia C, Iori A P, Boecklin F et al.. Fusarium infections in patients with severe aplastic anemia: review and implications for management.  Haematologica. 1999;  84 114-118
• 40 Torres H A, Bodey G P, Rolston K VI, Kantarjian H M, Raad I I, Kontoyiannis D P. Infections in patients with aplastic anemia: experience at a tertiary care cancer center.  Cancer. 2003;  98 86-93
• 41 Etzel R A. Mycotoxins.  JAMA. 2002;  287 425-427
• 42 Rosenstein Y, Kretschmer R R, Lafarge-Frayssinet C. Effect of Fusarium toxins, T2-toxin and diacetoxyscirpenol on murine T-independent immune responses.  Immunology. 1981;  44 555-560
• 43 Pitt J I. Toxigenic fungi: which are important?.  Med Mycol. 2000;  38(suppl 1) S17-S22
• 44 Sugiura Y, Sugita-Kouishi Y, Kumagai S, Reiss E. Experimental murine hyalohyphomycosis with soil-derived isolates of Fusarium solani .  Med Mycol. 2003;  41 241-247
• 45 Sudhir K, MacGregor J S, DeMarco T et al.. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries.  Circulation. 1994;  90 3018-3023
• 46 Kiryu H, Yoshida S, Suenaga Y, Asahi M. Invasion and survival of Fusarium solani in the dexamethasone-treated cornea of rabbits.  J Med Vet Mycol. 1991;  29 395-406
• 47 El-Ani A S. Disseminated infection caused by Fusarium solani in a patient with aplastic anemia.  N Y State J Med. 1990;  90 609-610
• 48 Segal B H, Walsh T J, Liu J M, Wilson J D, Kwon-Chung K J. Invasive infection with Fusarium chlamydosporum in a patient with aplastic anemia.  J Clin Microbiol. 1998;  36 1772-1776
• 49 Kontoyiannis D P, Wessel V C, Bodey G P, Rolston K V. Zygomycosis in the 1990s in a tertiary-care cancer center.  Clin Infect Dis. 2000;  30 851-856
• 50 Liu K, Howell D N, Perfect J R, Schell W A. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology.  Am J Clin Pathol. 1998;  109 45-54
• 51 Hayden R T, Isotalo P A, Parrett T et al.. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section.  Diagn Mol Pathol. 2003;  12 21-26
• 52 Van Burik J A, Myerson D, Schreckhise R W, Bowden R A. Panfungal PCR assay for detection of fungal infection in human blood specimens.  J Clin Microbiol. 1998;  36 1169-1175
• 53 Walsh T J, Francesconi A, Kasai M, Chanock S J. PCR and single-strand conformational polymorphism for recognition of medically important opportunistic fungi.  J Clin Microbiol. 1995;  33 3216-3220
• 54 Hennequin C, Abachin E, Symoens F et al.. Identification of Fusarium species involved in human infections by 28S rRNA gene sequencing.  J Clin Microbiol. 1999;  37 3586-3589
• 55 Kovacicova G, Spanik S, Kunova A et al.. Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients.  Scand J Infect Dis. 2001;  33 367-374
• 56 Trabasso P, Vigorito A C, De Souza C A, Moretti-Branchini M L. Invasive fungal infection in hematopoietic stem cell transplant recipients at a Brazilian university hospital. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; 2001 Abstract K-1248
• 57 Farina C, Vailati F, Manisco A, Goglio A. Fungaemia survey: a 10-year experience in Bergamo, Italy.  Mycoses. 1999;  42 543-548
• 58 Kontoyiannis D P, Sumoza D, Tarrand J, Bodey G P, Storey R, Raad I I. Significance of aspergillemia in patients with cancer: a 10-year study.  Clin Infect Dis. 2000;  31 188-189
• 59 Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management.  Clin Infect Dis. 2002;  35 909-920
• 60 Bodey G P, Boktour M, Mays S et al.. Skin lesions associated with Fusarium infection.  J Am Acad Dermatol. 2002;  47 659-666
• 61 Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex J H. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.  J Clin Microbiol. 1999;  37 3946-3951
• 62 Anaissie E J, Hachem R, Legrand C, Legenne P, Nelson P, Bodey G P. Lack of activity of amphotericin B in systemic murine fusarial infection.  J Infect Dis. 1992;  165 1155-1157
• 63 Guarro J, Pujol I, Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani .  Antimicrob Agents Chemother. 1999;  43 1256-1257
• 64 Paphitou N I, Ostrosky-Zeichner L, Paetznick V L, Rodriguez J R, Chen E, Rex J H. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.  Antimicrob Agents Chemother. 2002;  46 3298-3300
• 65 Kontoyiannis D P, Lewis R E. Antifungal drug resistance of pathogenic fungi.  Lancet. 2002;  359 1135-1144
• 66 Koizumi T, Kubo K, Kaneki T et al.. Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B.  Antimicrob Agents Chemother. 1998;  42 1597-1600
• 67 Mohammedi I, Gachot B, Grossin M, Marche C, Wolff M, Vachon F. Overwhelming myocarditis due to Fusarium oxysporum following bone marrow transplantation.  Scand J Infect Dis. 1995;  27 643-644
• 68 Ortoneda M, Capilla J, Pastor F J, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis.  Antimicrob Agents Chemother. 2002;  46 2273-2275
• 69 Walsh T J, Hiemenz J W, Seibel N L et al.. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.  Clin Infect Dis. 1998;  26 1383-1396
• 70 Lewis R E, Wiederhold N P. The solubility ceiling: a possible rationale for continuous infusion amphotericin B therapy?.  Clin Infect Dis. 2003;  37 871-872
• 71 Bekersky I, Fielding R M, Dressler D E, Lee J W, Buell D N, Walsh T J. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.  Antimicrob Agents Chemother. 2002;  46 834-840
• 72 Reuben A, Anaissie E, Nelson P E et al.. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method.  Antimicrob Agents Chemother. 1989;  33 1647-1649
• 73 Hirose H, Terasaki H, Awaya S, Yasuma T. Treatment of fungal corneal ulcers with amphotericin B ointment.  Am J Ophthalmol. 1997;  124 836-838
• 74 Barret J P, Ramzy P I, Heggers J P, Villareal C, Herndon D N, Desai M H. Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents.  Burns. 1999;  25 505-508
• 75 Johnson E M, Szekely A, Warnock D W. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.  J Antimicrob Chemother. 1998;  42 741-745
• 76 Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.  J Clin Microbiol. 1998;  36 2950-2956
• 77 Espinel-Ingroff A, Boyle K, Sheehan D J. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.  Mycopathologia. 2001;  150 101-115
• 78 Fothergill A W, Rinaldi M G, Schwocho L R, Ohya S. Comparison of the investigational azole CS-758 (R-120758) to amphotericin B, fluconazole, and itraconazole against 250 mould fungi. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; 2001 Abstract J-822
• 79 Huczko E, Minassian B, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; 2001 Abstract J-810
• 80 Lozano-Chiu M, Arikan S, Paetznick V L, Anaissie E J, Loebenberg D, Rex J H. Treatment of murine fusariosis with SCH 56592.  Antimicrob Agents Chemother. 1999;  43 589-591
• 81 Marco F, Pfaller M A, Messer S A, Jones R N. In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi.  Mycopathologia. 1998;  141 73-77
• 82 Pfaller M A, Messer S A, Hollis R J, Jones R N. and the Sentry Participants Group . Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B tested against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from the SENTRY antimicrobial surveillance program, 2000.  Antimicrob Agents Chemother. 2002;  46 1032-1037
• 83 Reyes G H, Long L, Hossain M, Ghannoum M A. Evaluation of voriconazole efficacy in the treatment of murine fusariosis. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; 2001 Abstract J-1604
• 84 Perfect J R, Marr K A, Walsh T J et al.. Voriconazole treatment for less-common, emerging, or refractory fungal infections.  Clin Infect Dis. 2003;  36 1122-1131
• 85 Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.  Clin Infect Dis. 2003;  37 311-313
• 86 Hachem R, Raad I I, Afif C et al.. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada; 2000 Abstract J-1109
• 87 Johnson E M, Szekely A, Warnock D W. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.  Antimicrob Agents Chemother. 1999;  43 1260-1263
• 88 Capilla J, Ortoneda M, Pastor F J, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.  Antimicrob Agents Chemother. 2001;  45 2635-2637
• 89 Arikan S, Lozano-Chiu M, Paetznick V, Rex J H. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.  Antimicrob Agents Chemother. 2001;  45 327-330
• 90 Del Poeta M, Schell W A, Perfect J R. In vitro antifungal activity of pneumocandin L-743, 872 against a variety of clinically important molds.  Antimicrob Agents Chemother. 1997;  41 1835-1836
• 91 Pfaller M A, Marco F, Messer S A, Jones R N. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.  Diagn Microbiol Infect Dis. 1998;  30 251-255
• 92 Tawara S, Ikeda F, Maki K et al.. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.  Antimicrob Agents Chemother. 2000;  44 57-62
• 93 Apostolidis J, Bouzani M, Platsouka E et al.. Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin.  Clin Infect Dis. 2003;  36 1349-1350
• 94 Li R K, Rinaldi M G. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole.  Antimicrob Agents Chemother. 1999;  43 1401-1405
• 95 Lionakis M S, Lewis R E, Samonis G, Kontoyiannis D P. Pentamidine is active in vitro against Fusarium species.  Antimicrob Agents Chemother. 2003;  47 3252-3259
• 96 Petranyi G, Meingassner J G, Mieth H. Activity of terbinafine in experimental fungal infections of laboratory animals.  Antimicrob Agents Chemother. 1987;  31 1558-1561
• 97 Del Poeta M, Schell W A, Dykstra C C et al.. In vitro antifungal activities of a series of dication-substituted carbazoles, furans, and benzimidazoles.  Antimicrob Agents Chemother. 1998;  42 2503-2510
• 98 Merz W G, Karp J E, Hoagland M, Jett-Goheen M, Junkins J M, Hood A F. Diagnosis and successful treatment of fusariosis in the compromised host.  J Infect Dis. 1988;  158 1046-1055
• 99 Arikan S, Lozano-Chiu M, Paetznick V, Rex J H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.  Antimicrob Agents Chemother. 2002;  46 245-247
• 100 Clancy C J, Nguyen M H. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis.  J Antimicrob Chemother. 1998;  41 127-130
• 101 Stern G A. In vitro antibiotic synergism against ocular fungal isolates.  Am J Ophthalmol. 1978;  86 359-367
• 102 Farmaki E, Roilides E. Immunotherapy in patients with systemic mycoses: a promising adjunct.  BioDrugs. 2001;  15 207-214
• 103 Rodriguez-Adrian L J, Grazziutti M L, Rex J H, Anaissie E J. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?.  Clin Infect Dis. 1998;  26 1270-1278
• 104 Roilides E, Maloukou A, Gil-Lamaignere C, Winn R M, Panteliadis C, Walsh T J. Differential effects of interleukin 15 on hyphal damage of filamentous fungi induced by human neutrophils. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; 2001 Abstract J-468
• 105 Winn R M, Maloukou A, Gil-Lamaignere C, Panteliadis C, Roilides E. The Eurofung Network. Interferon-gamma and granulocyte-macrophage colony stimulating factor enhance hyphal damage of Aspergillus and Fusarium spp by human neutrophils. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL; 2001 Abstract J-134
• 106 Heinz T, Perfect J, Schell W, Ritter E, Ruff G, Serafin D. Soft-tissue fungal infections: surgical management of 12 immunocompromised patients.  Plast Reconstr Surg. 1996;  97 1391-1399